| Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection (NCT03487848) | Bristol-Myers Squibb | 2018-06-25 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis (NCT03486899) | Bristol-Myers Squibb | 2018-06-19 |
| A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis (NCT03486912) | Bristol-Myers Squibb | 2018-06-12 |
| An Investigational Study to Evaluate the Effect of Rifampin on the Singe Dose of Experimental Medication BMS-986224 in Healthy Participants (NCT03563950) | Bristol-Myers Squibb | 2018-06-01 |
| An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects (NCT03541564) | Bristol-Myers Squibb | 2018-05-30 |
| An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread (NCT03459222) | Bristol-Myers Squibb | 2018-05-30 |
| An Investigational Study of Experimental Medication BMS-986231 Given in Participants With Different Levels of Liver Function (NCT03515980) | Bristol-Myers Squibb | 2018-05-25 |
| An Immuno-Therapy Study of Experimental Medication BMS-986205 Given With Nivolumab With or Without Chemotherapy Compared to Chemotherapy in Participants With Previously Untreated Stage IV or Recurrent Non-Small Cell Lung Cancer (NCT03417037) | Bristol-Myers Squibb | 2018-05-24 |
| Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) (NCT03500562) | Bristol-Myers Squibb | 2018-05-08 |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment (NCT03335540) | Bristol-Myers Squibb | 2018-05-07 |
| Study to Determine if the Flu Vaccine Increases the Risk of Muscle Damage in Participants Taking Drugs That Block Certain Proteins Made by Some Types of Immune System Cells (NCT03644498) | Bristol-Myers Squibb | 2018-05-02 |
| Extension Study of Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Previously Enrolled in PIONEER (NCT03496168) | Bristol-Myers Squibb | 2018-04-26 |
| Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules (NCT03509883) | Bristol-Myers Squibb | 2018-04-26 |
| A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (NCT03383458) | Bristol-Myers Squibb | 2018-04-18 |
| A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis (NCT03457792) | Bristol-Myers Squibb | 2018-04-17 |
| A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (NCT03470922) | Bristol-Myers Squibb | 2018-04-11 |
| Study of the Safety of Orencia in Japanese Children and Adolescents With Active Juvenile Arthritis of Unknown Origin (NCT03466814) | Bristol-Myers Squibb | 2018-04-06 |
| An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed (NCT03444753) | Bristol-Myers Squibb | 2018-04-05 |
| An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck (NCT03386838) | Bristol-Myers Squibb | 2018-03-28 |
| A Study of Experimental Medication BMS-986231 in Patients With Different Levels of Kidney Function (NCT03332186) | Bristol-Myers Squibb | 2018-03-15 |
| A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (NCT03048136) | Bristol-Myers Squibb | 2018-03-09 |
| An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread (NCT03446040) | Bristol-Myers Squibb | 2018-03-08 |
| Study of Nivolumab for Advanced Cancers in India (NCT03444766) | Bristol-Myers Squibb | 2018-03-06 |
| An Investigational Study of Cyclosporine on Experimental Medication BMS-986165 in Healthy Male Participants (NCT03419910) | Bristol-Myers Squibb | 2018-03-05 |
| Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants (NCT03419143) | Bristol-Myers Squibb | 2018-03-02 |
| Single-dose Pharmacokinetics of BMS-986177 in Participants With Hepatic Impairment Compared to Healthy Participants (NCT02982707) | Bristol-Myers Squibb | 2018-03-01 |
| A Study of Patients Hospitalized With Acute Heart Failure With Reduced Ejection Fraction (HFrEF) (NCT03515655) | Bristol-Myers Squibb | 2018-02-21 |
| An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread (NCT03414983) | Bristol-Myers Squibb | 2018-02-20 |
| A Study of Experimental Medication BMS-986036 Given to Healthy Participants (NCT03445208) | Bristol-Myers Squibb | 2018-02-14 |
| Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants (NCT03568435) | Bristol-Myers Squibb | 2018-02-14 |
| Effectiveness and Safety of Nivolumab in Participants That Have Head and Neck Cancer That Has Come Back or Has Spread (NCT03569436) | Bristol-Myers Squibb | 2018-02-14 |
| A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C (NCT03420768) | Bristol-Myers Squibb | 2018-02-14 |
| A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers (NCT03400332) | Bristol-Myers Squibb | 2018-02-12 |
| A Study of Experimental Medication BMS-986278 Given to Healthy Participants (NCT03429933) | Bristol-Myers Squibb | 2018-02-07 |
| v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 (NCT03447990) | Bristol-Myers Squibb | 2018-02-06 |
| An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread (NCT03377361) | Bristol-Myers Squibb | 2018-01-31 |
| Description of Joint Population and Assessment of Impact on Health Status of Orencia in Patients With Rheumatoid Arthritis in France. A Database Analysis Based on SFR's ORA Long-term Cohort Study (NCT01694693) | Bristol-Myers Squibb | 2018-01-31 |
| Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer (NCT03455452) | Bristol-Myers Squibb | 2018-01-21 |
| A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B (NCT03426618) | Bristol-Myers Squibb | 2018-01-12 |
| A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients (NCT03402087) | Bristol-Myers Squibb | 2018-01-08 |
| The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany (NCT03205722) | Bristol-Myers Squibb | 2018-01-05 |
| A Study to Evaluate the Bioavailability of BMS-986205 (NCT03374228) | Bristol-Myers Squibb | 2018-01-04 |
| Elotuzumab Safety Surveillance In Japanese Patients With Relapse Or Refractory Multiple Myeloma (NCT02976493) | Bristol-Myers Squibb | 2018-01-01 |
| Real-world Incidence Proportion of Hepatic Toxicity and All Adverse Drug Reactions (ADRs) in Japanese Patients Receiving Daclatasvir (DCV) Trio Therapy (NCT03071133) | Bristol-Myers Squibb | 2018-01-01 |
| A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia (NCT03195491) | Bristol-Myers Squibb | 2017-12-25 |
| A Study in Healthy Participants Evaluating the Absorption of a BMS-986205 Tablet Into the Bloodstream Compared to a Reference Tablet (NCT03378310) | Bristol-Myers Squibb | 2017-12-21 |
| An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (NCT03338790) | Bristol-Myers Squibb | 2017-12-19 |
| A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (NCT03336216) | Bristol-Myers Squibb | 2017-12-18 |
| Nivolumab or Nivolumab Plus Cisplatin, in Combination With Radiotherapy in Patients With Cisplatin-ineligible or Eligible Locally Advanced Squamous Cell Head and Neck Cancer (NCT03349710) | Bristol-Myers Squibb | 2017-12-15 |
| Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom (NCT03448497) | Bristol-Myers Squibb | 2017-12-14 |
| Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer (NCT03505515) | Bristol-Myers Squibb | 2017-12-07 |
| An Investigational Immuno-Therapy Study of Experimental Medication BMS-986277 Given Alone and in Combination With Nivolumab in Epithelial Cancers (NCT03363776) | Bristol-Myers Squibb | 2017-12-06 |
| A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid Tumors (NCT03369223) | Bristol-Myers Squibb | 2017-12-06 |
| A Study Using Healthy Volunteers Comparing Belatacept Which Has Been Manufactured By 2 Different Processes (NCT03375138) | Bristol-Myers Squibb | 2017-12-04 |
| Study of Chinese Newly Diagnosed Participants With Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) (NCT03509896) | Bristol-Myers Squibb | 2017-11-30 |
| An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma (NCT03329846) | Bristol-Myers Squibb | 2017-11-30 |
| Effectiveness of Oral Anticoagulants in Elderly Patients With Non-Valvular Atrial Fibrillation and Heart Failure (NCT03508271) | Bristol-Myers Squibb | 2017-11-30 |
| A Study of Continuous Infusions of HNO (Nitroxyl) Donor in Patients With Heart Failure and Impaired Systolic Function (NCT03357731) | Bristol-Myers Squibb | 2017-11-30 |
| An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer (NCT03351231) | Bristol-Myers Squibb | 2017-11-27 |
| A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects (NCT03346837) | Bristol-Myers Squibb | 2017-11-22 |
| Evaluate the Pharmacokinetics of BMS-986177 From Two Formulations in Healthy Participants (NCT03362437) | Bristol-Myers Squibb | 2017-11-15 |
| A Study of Experimental Medication BMS-986235 in Healthy Subjects (NCT03335553) | Bristol-Myers Squibb | 2017-11-15 |
| A Study to Assess the Absorption of a Single Dose of BMS-986205 in Healthy Volunteers When Administered as a Crushed Tablet Orally or Crushed Tablet Suspension Via Nasogastric Tube, as Compared to a Tablet (NCT03362411) | Bristol-Myers Squibb | 2017-11-09 |
| A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis (NCT03329885) | Bristol-Myers Squibb | 2017-11-02 |
| An Investigational Study to Assess the Effect of BMS-986177 on Aspirin in Healthy Participants (NCT03341390) | Bristol-Myers Squibb | 2017-10-18 |
| An Investigational Study to Assess the Effect of a Light Meal and a High-Fat Meal on the Absorption of BMS-986205 in Healthy Participants (NCT03312426) | Bristol-Myers Squibb | 2017-10-09 |
| Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia (NCT03663829) | Bristol-Myers Squibb | 2017-10-04 |
| Screening for Atrial Fibrillation (AF)-Potential Patients to Increase AF Detection Rate (NCT03313167) | Bristol-Myers Squibb | 2017-09-29 |
| A Study of BMS-986224 in Healthy Subjects and Heart Failure Patients With Reduced Ejection Fraction (NCT03281122) | Bristol-Myers Squibb | 2017-09-22 |
| An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus (NCT03252587) | Bristol-Myers Squibb | 2017-09-21 |
| A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation (NCT03254784) | Bristol-Myers Squibb | 2017-09-13 |
| The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients (NCT03262740) | Bristol-Myers Squibb | 2017-09-11 |
| A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors (NCT03251924) | Bristol-Myers Squibb | 2017-09-01 |
| Study to Describe Risk of Bleeding in Patients Depending on the Different Anticoagulant Therapy They Are on for Atrial Fibrillation (AF) (NCT03508258) | Bristol-Myers Squibb | 2017-09-01 |
| The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients (NCT03262727) | Bristol-Myers Squibb | 2017-09-01 |
| A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (NCT03215706) | Bristol-Myers Squibb | 2017-08-24 |
| Study of the Sudden Heart Failure Participant Population in the US (NCT03566264) | Bristol-Myers Squibb | 2017-08-22 |
| A Study of BMS-986195 in Healthy Male Subjects (NCT03245515) | Bristol-Myers Squibb | 2017-08-15 |
| A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors (NCT03184870) | Bristol-Myers Squibb | 2017-08-08 |
| A Study to Investigate the Effectiveness of an Education Support Program on Medication Adherence in Italian Real Life Rheumatoid Arthritis (RA) Patients Treated With Subcutaneous (SC) Abatacept (NCT03188081) | Bristol-Myers Squibb | 2017-08-02 |
| A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors (NCT03195478) | Bristol-Myers Squibb | 2017-08-02 |
| A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (NCT03141177) | Bristol-Myers Squibb | 2017-07-23 |
| Pharmacokinetics and Metabolism Study in Healthy Male Participants (NCT03247283) | Bristol-Myers Squibb | 2017-07-19 |
| Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States (NCT03045120) | Bristol-Myers Squibb | 2017-07-19 |
| Study to Assess the Safety of Nivolumab in the Treatment of Metastatic Melanoma, Lung Cancer, Renal Cancer, Squamous Cell Carcinoma of the Head and Neck, and Chronic Hodgkin Lymphoma in Adults in Mexico (NCT03161613) | Bristol-Myers Squibb | 2017-07-17 |
| A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA) (NCT03192969) | Bristol-Myers Squibb | 2017-07-15 |
| A Safety Study of Lirilumab in Combination With Nivolumab or in Combination With Nivolumab and Ipilimumab in Advanced and/or Metastatic Solid Tumors (NCT03203876) | Bristol-Myers Squibb | 2017-07-14 |
| Evaluate Pharmacokinetics and Safety of BMS-986177 in Participants With Normal Renal Function and With Moderate or Severe Renal Impairment (NCT03196206) | Bristol-Myers Squibb | 2017-07-13 |
| A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney (NCT03138512) | Bristol-Myers Squibb | 2017-07-07 |
| A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus Cisplatin (NCT03143153) | Bristol-Myers Squibb | 2017-06-29 |
| To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants (NCT03224260) | Bristol-Myers Squibb | 2017-06-28 |
| A Study to Test the Effects of BMS-986036 on the Body in Healthy Japanese and Non-Japanese Subjects (NCT03198182) | Bristol-Myers Squibb | 2017-06-28 |
| A Study of Nivolumab Plus Brentuximab Vedotin Versus Brentuximab Vedotin Alone in Patients With Advanced Stage Classical Hodgkin Lymphoma, Who Are Relapsed/ Refractory or Who Are Not Eligible for Autologous Stem Cell Transplant, (NCT03138499) | Bristol-Myers Squibb | 2017-06-26 |
| A Study of BMS-986205 Given in Combination With Nivolumab in Patients With Advanced Tumors (NCT03192943) | Bristol-Myers Squibb | 2017-06-23 |
| Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants (NCT03210909) | Bristol-Myers Squibb | 2017-06-22 |
| A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread (NCT03098550) | Bristol-Myers Squibb | 2017-06-15 |
| A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies (NCT03130959) | Bristol-Myers Squibb | 2017-06-12 |
| Safety Study of Nivolumab to Treat Advanced or Metastatic Non-small Cell Lung Cancer (NCT03090737) | Bristol-Myers Squibb | 2017-06-02 |
| A Study of Cabiralzumab Given by Itself or With Nivolumab in Advanced Cancer or Cancer That Has Spread (NCT03158272) | Bristol-Myers Squibb | 2017-05-25 |
| A Study to Evaluate Safety of Single Doses of BMS-986177 in Patients With End Stage Renal Disease (ESRD) Treated With Hemodialysis (NCT03000673) | Bristol-Myers Squibb | 2017-05-23 |